Proteomic and Oncogenic Biomarkers in Gastrointestinal Cancer
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Biomarkers".
Deadline for manuscript submissions: 31 March 2026 | Viewed by 229
Special Issue Editors
Interests: inflammation; malignant diseases; diagnosis; tumor biomarkers; gastrointestinal cancer
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Gastrointestinal (GI) cancers are among the most prevalent and lethal malignancies worldwide, with aggressive progression and poor prognosis. GI neoplasms are complex diseases with dysregulation of the cellular signaling that controls proliferation and apoptosis. These may be caused by various genetic, genomic, and epigenetic alterations at the cellular or tissue levels. Despite advances, early detection remains challenging. Proteomic and oncogenic biomarkers, especially those identified via proteomic approaches, are vital for understanding tumor initiation, progression, and treatment response. Proteomic analysis reveals changes in protein levels and function, helping to better understand GI cancer progression. The search for new oncogenic and proteomic biomarkers can enhance early diagnosis, prognosis, and personalized treatment.
This Special Issue highlights the latest discoveries in these areas, emphasizing their clinical relevance and the importance of biomarker research in improving patient outcomes in GI oncology.
Dr. Marta Lukaszewicz-Zajac
Guest Editor
Adrianna Romanowicz
Guest Editor Assistant
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- tumor biomarkers
- early detection
- tumor progression
- carcinogenesis
- inflammatory mediators
- gastrointestinal cancer
- prognostic biomarkers
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
